Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

118.45 +0.99 (+0.84%)
Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,876,480
Open 117.27
Bid (Size) 118.29 (2)
Ask (Size) 118.87 (1)
Prev. Close 117.46
Today's Range 117.15 - 118.75
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill

Performance

YTD
+4.60%
+4.60%
1 Month
+4.70%
+4.70%
3 Month
-5.65%
-5.65%
6 Month
-6.70%
-6.70%
1 Year
+8.69%
+8.69%

More News

Read More
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Via Benzinga
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
Via Benzinga
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Options: An Unlikely Source Of Income
Via Talk Markets
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
From Merck & Co., Inc.
Via Business Wire
Dow Jones Industrial Average Pares Recent Gains As Investors Take A Pause
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Dividend Stocks to Earn Income Every Month
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
Via The Motley Fool
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
From Merck & Co., Inc.
Via Business Wire
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
From Merck & Co., Inc.
Via Business Wire
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
MarketBeat Week in Review – 8/19 - 8/23
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Via Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Via Talk Markets
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.